Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Pfizer’s mixed Q3; delayed US approval for Janssen/Legend’s CAR-T; promising new data in RSV; Dr Reddy’s lays out more COVID product plans; and experts dissect decentralized trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 October 2021, including: Pfizer Inc.’s mixed Q3; delayed US approval for Janssen Pharmaceutical Cos./Legend Biotech Corp.’s CAR-T; promising new data in RSV; Dr. Reddy's Laboratories Ltd.’s lays out more COVID-19 product plans; and experts dissect decentralized trials.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Comirnaty Gives Booster Shot To Pfizer Q3 Sales" - Scrip, 2 Nov, 2021.)

(Also see "Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use" - Scrip, 1 Nov, 2021.)

(Also see "Dr Reddy’s Gears For Sputnik Pediatric Shot, Molnupiravir Upside" - Scrip, 1 Nov, 2021.)

(Also see "Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?" - Scrip, 3 Nov, 2021.)

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts